+ Watch MELA
on My Watchlist
A medical device company which focuses on designing and development of a non-invasive, point-of-care instrument to assist in the early diagnosis of melanoma.
Back over 4 again, MELA? Well, here's your smack to the mouth. I've analyzed the pivotal trial data for MelaFind and found that it minimally reduces the number of biopsies at the cost of missing a very small number of melanomas. The device is essentially useless by cost-benefit analysis.I believe MelaFind hopes to find enough unethical dermatologists who will use this quack device as long as it makes them money. That's not a completely outlandish expectation, but I think it is less probable than the outcome that insurance companies and governmental regulators will find ways to slow and prevent reimbursement for use of the device. Let's hope for everyone's sake that in this case, the system works.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions